Sarcomatoid

Sarcomatoid is a histologic subtype of mesothelioma in which the tumor cells are long and spindle-shaped, resembling the cells of a soft-tissue sarcoma rather than typical mesothelial tissue. It is the least common of the three main mesothelioma subtypes (sarcomatoid, epithelioid, and biphasic) and generally carries the most aggressive course and shortest survival. A rare variant called desmoplastic mesothelioma falls within this category.

Origin

The term combines "sarcoma," from the Greek sarx (flesh) and -oma (tumor), with the suffix "-oid" (resembling). Pathologists adopted it in the 20th century to describe tumors that are not true sarcomas but mimic their spindle-cell appearance under the microscope.

Significance in Asbestos Context

For patients, the sarcomatoid designation in a pathology report is one of the most important pieces of information in the chart because it directly shapes prognosis and treatment options. Sarcomatoid tumors generally respond less well to surgery and chemotherapy than epithelioid tumors, and many surgical centers will not offer aggressive procedures like extrapleural pneumonectomy or pleurectomy/decortication when the subtype is purely sarcomatoid; immunotherapy combinations (such as nivolumab plus ipilimumab) have become a first-line option in part because sarcomatoid disease responds relatively better to immunotherapy than to traditional chemotherapy. In legal claims, the subtype is medically relevant evidence of the diagnosis and its severity, and it often affects the urgency of moving a case forward, including requests for trial preference based on health condition. Because the diagnosis hinges on how a pathologist reads the tissue, a second pathology review at a mesothelioma specialty center is often worthwhile before treatment and litigation decisions are finalized.

Example Sentence

After her biopsy came back as sarcomatoid mesothelioma, her oncologist referred her to a specialty center for a second pathology opinion and a discussion of immunotherapy rather than surgery.

Related Terms

Mesothelioma, Epithelioid, Biphasic, Desmoplastic Mesothelioma, Immunohistochemistry, Histology

Notes

• Ask your oncologist or pathologist for a copy of the full pathology report and request that the slides be sent to a mesothelioma specialty center (such as a National Cancer Institute–designated cancer center) for a confirmatory second review before committing to a treatment plan.
• Ask specifically whether immunotherapy (for example, nivolumab plus ipilimumab) is appropriate, since sarcomatoid disease often responds better to immunotherapy than to platinum-pemetrexed chemotherapy alone.
• Preserve all pathology reports, immunohistochemistry stain results, and imaging. These documents are central both to treatment decisions and to any asbestos claim, and they may support a request for trial preference due to the aggressive nature of the disease.
• If the report mentions "desmoplastic" features, ask whether the tumor meets criteria for desmoplastic mesothelioma, a sarcomatoid variant that can be especially difficult to distinguish from benign fibrous pleuritis.